JUNSHI BIO (688180.SH): FDA Approves Clinical Trial Application for JS212 for the Treatment of Advanced Solid Tumors

16:01 14/12/2025

Kingen Biotech (688180.SH) announced that the company has received a notification from the U.S. Food and Drug Administration (FDA) that its EGFR/HER3 bispecific antibody-drug conjugate (code: JS212) for the treatment of advanced solid tumors has been approved for clinical trial application by the FDA.

JUNSHI BIO (688180.SH) announced that the company has received a notification from the Food and Drug Administration (FDA) of the United States. The clinical trial application for the EGFR/HER3 bispecific antibody-drug conjugate (code: JS212) for the treatment of advanced solid tumors has been approved by the FDA.

How to predict the market trend for the New Year? How to strategize for opportunities next year? The strategies from the top ten securities firms are here.

Hong Kong-listed company 18C Corporation is making waves in the Physical AI sector by holding a hearing on May 1st.

FENBI (02469) partners with Huatu strategically to reshape the valuation logic of top-level collaboration in vocational education.

How to predict the market trend for the New Year? How to strategize for opportunities next year? The strategies from the top ten securities firms are here.

Hong Kong-listed company 18C Corporation is making waves in the Physical AI sector by holding a hearing on May 1st.

FENBI (02469) partners with Huatu strategically to reshape the valuation logic of top-level collaboration in vocational education.